Fennec Pharmaceuticals Inc (FENC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $410.25M
Last updated: Nov 17, 2026 at 11:05 AM ET
Fennec Pharmaceuticals Inc (FENC) Financials: Revenue, Profit and Cash Flow
Fennec Pharmaceuticals reported revenue of $44.64M for the fiscal year ended Dec 31, 2025, down 6.1% from the year before. That year, net income was -$9.74M with a net margin of -21.8%, operating cash flow was -$12.47M and free cash flow was -$12.47M. The quarter ended Sep 30, 2026 had revenue of $19.61M and net income of $4.64M.
Revenue and Margins
The operating margin was -14.1% in the fiscal year ended Dec 2025. Over the 5 years to Dec 2025, revenue grew from $170.00K, a compound annual rate of 204.7%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $44.64M | -6.1% | 91.6% | -14.1% | -21.8% |
| Dec 2024 | $47.54M | +123.7% | 93.3% | 5.4% | -0.9% |
| Dec 2023 | $21.25M | +1284.5% | 94.1% | -60.1% | -75.5% |
| Dec 2022 | $1.53M | N/A | 94.4% | -1471.6% | -1544.9% |
| Dec 2021 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2020 | $170.00K | N/A | 100.0% | -10520.6% | -10652.4% |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.64M | $47.54M | $21.25M | $1.53M | $0 | $170.00K | $0 | $0 | $0 | $0 |
| Cost of revenue | $3.76M | $3.18M | $1.26M | $86.00K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $40.88M | $44.35M | $19.99M | $1.45M | $0 | $170.00K | $0 | $0 | $0 | $0 |
| Research and development | $250.00K | $307.00K | $56.00K | $3.53M | $4.98M | $5.11M | $5.61M | $5.01M | $1.94M | $472.00K |
| Operating income | -$6.28M | $2.57M | -$12.77M | -$22.59M | -$17.22M | -$17.89M | -$13.01M | -$10.41M | -$6.95M | -$2.87M |
| Net income | -$9.74M | -$436.00K | -$16.05M | -$23.71M | -$17.35M | -$18.11M | -$12.78M | -$9.89M | -$7.05M | -$2.79M |
| EBITDA | -$6.09M | $3.36M | -$12.52M | -$22.45M | N/A | -$17.38M | N/A | -$10.24M | N/A | -$2.80M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.61M | $17.87M | $15.11M | $13.78M | $12.46M | $9.65M | $8.75M | $7.92M | $6.97M | $7.26M | $25.38M | $9.73M |
| Gross profit | $18.77M | $17.15M | $14.54M | $12.01M | $11.80M | $8.69M | $8.38M | $7.26M | $5.62M | $6.65M | $24.83M | $9.05M |
| Operating income | $4.65M | $1.74M | -$119.00K | -$2.55M | -$189.00K | -$2.73M | -$808.00K | -$934.00K | -$5.20M | -$5.04M | $13.74M | -$1.82M |
| Net income | $4.64M | $1.97M | $201.00K | -$4.79M | -$638.00K | -$3.15M | -$1.17M | -$1.99M | -$5.74M | -$5.55M | $12.84M | -$2.68M |
Balance Sheet
As of Dec 2025, cash and equivalents of $36.79M were 52.1% of total assets of $70.55M, against total liabilities of $35.08M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $70.55M | $44.95M | $26.86M | $26.94M | $22.41M | $31.42M | $14.15M | $22.95M | $28.40M | $3.97M |
| Current assets | $67.04M | $44.12M | $26.86M | $26.73M | $22.39M | $31.42M | $13.88M | $22.95M | $28.40M | $3.97M |
| Cash and equivalents | $36.79M | $26.63M | $13.27M | $23.77M | $21.10M | $30.34M | $13.65M | $22.78M | $28.26M | $3.93M |
| Total liabilities | $35.08M | $50.82M | $38.49M | $29.51M | $6.64M | $2.35M | $2.27M | $1.64M | $1.64M | $402.00K |
| Short-term debt | N/A | $2.00K | $21.00K | N/A | $12.00K | N/A | N/A | N/A | $167.00K | $33.00K |
| Long-term debt | N/A | -$139.00K | -$288.00K | -$361.00K | $4.99M | N/A | N/A | N/A | $0 | $0 |
| Shareholder equity | $35.47M | -$5.87M | -$11.62M | -$2.57M | $15.77M | $29.07M | $11.88M | $21.31M | $26.76M | $3.57M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $83.54M | $75.75M | $71.82M | $70.55M | $49.26M | $44.88M | $46.40M | $44.95M | $58.92M | $63.16M | $69.19M | $26.86M |
| Total liabilities | $34.35M | $33.31M | $34.15M | $35.08M | $53.75M | $52.34M | $52.28M | $50.82M | $64.09M | $64.52M | $66.18M | $38.49M |
| Cash and equivalents | $48.68M | $41.25M | $40.18M | $36.79M | $21.95M | $18.70M | $22.68M | $26.63M | $40.32M | $43.05M | $51.18M | $13.27M |
| Shareholder equity | $49.19M | $42.44M | $37.67M | $35.47M | -$4.49M | -$7.46M | -$5.88M | -$5.87M | -$5.17M | -$1.36M | $3.01M | -$11.62M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.47M | $26.98M | -$17.14M | -$18.06M | -$14.22M | -$15.60M | -$9.06M | -$7.83M | -$3.64M | -$2.12M |
| Free cash flow | -$12.47M | $26.98M | N/A | -$18.06M | -$14.22M | -$15.60M | -$9.06M | -$7.83M | -$3.64M | -$2.12M |
| Dividends paid | N/A | N/A | N/A | $529.16K | N/A | N/A | N/A | N/A | $0 | $0 |
| Share repurchases | N/A | N/A | N/A | N/A | $41.00K | $140.00K | $71.00K | $0 | N/A | N/A |
| Financing cash flow | $22.63M | -$13.62M | $6.64M | $20.73M | $4.98M | $32.29M | -$71.00K | $2.35M | $27.98M | $5.11M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $6.68M | $50.00K | $2.38M | -$5.96M | $1.49M | -$3.69M | -$4.32M | -$1.47M | -$2.21M | -$8.39M | $39.05M | -$4.86M |
| Capital expenditures | N/A | N/A | $1 | $0 | $0 | $0 | $0 | $0 | N/A | N/A | $0 | $0 |
| Free cash flow | N/A | N/A | $2.38M | -$5.96M | $1.49M | -$3.69M | -$4.32M | -$1.47M | N/A | N/A | $39.05M | -$4.86M |
Frequently Asked Questions About FENC
What is Fennec Pharmaceuticals' annual revenue?
Fennec Pharmaceuticals reported revenue of $44.64M for the fiscal year ended Dec 31, 2025.
How fast is Fennec Pharmaceuticals' revenue growing?
Revenue was down 6.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 207.5%.
Is Fennec Pharmaceuticals profitable?
No. Fennec Pharmaceuticals reported net income of -$9.74M for the fiscal year ended Dec 31, 2025, with a net margin of -21.8%.
How much free cash flow does FENC generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$12.47M minus capital expenditures of $0 produced free cash flow of -$12.47M.
How much debt does Fennec Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported cash and equivalents of $36.79M.
FENC pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors